Cargando…

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Detalles Bibliográficos
Autores principales:	Rakocevic, Goran, Martinez-Outschoorn, Ubaldo, Dalakas, Marinos C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886834/ https://www.ncbi.nlm.nih.gov/pubmed/29629397 http://dx.doi.org/10.1212/NXI.0000000000000460

Ejemplares similares

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies
por: Dalakas, Marinos C.
Publicado: (2018)

Repeated treatments with rituximab in a patient with amyloid-like IgM deposition neuropathy
por: Kadoya, Masato, et al.
Publicado: (2016)

Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy
por: Amaador, Karima, et al.
Publicado: (2022)

Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen‐specific glycopolymer
por: Aliu, Butrint, et al.
Publicado: (2020)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study
por: Hänggi, Pascal, et al.
Publicado: (2021)

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2021)

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
por: Dalakas, Marinos C.
Publicado: (2022)

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
por: Rakocevic, Goran, et al.
Publicado: (2019)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies
por: Falzone, Yuri M., et al.
Publicado: (2018)

Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy
por: Pascual-Goñi, Elba, et al.
Publicado: (2019)

Combined Central and Peripheral Demyelination With IgM Anti–Neurofascin 155 Antibodies: Case Report
por: Pegat, Antoine, et al.
Publicado: (2022)

Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis
por: Chalmoukou, Konstantina, et al.
Publicado: (2015)

Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
por: Oaklander, Anne Louise, et al.
Publicado: (2022)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Anti-ganglioside Complex IgM Antibodies in Multifocal Motor Neuropathy Post-influenza Vaccination
por: Suresh, Krithika, et al.
Publicado: (2022)

Spinal Cord Impairment in Anti-Mag Neuropathy: Evidence from Somatosensory Evoked Potentials
por: Boscarino, Marilisa, et al.
Publicado: (2020)

Author Correction: Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy
por: Pascual-Goñi, Elba, et al.
Publicado: (2021)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
por: Schmidt, Karsten, et al.
Publicado: (2016)

Rituximab Improves Subclinical Temporal Dispersion of Distal Compound Muscle Action Potential in Anti-MAG/SGPG Neuropathy Associated with Waldenström Macroglobulinemia: A Case Report
por: Kodaira, Minori, et al.
Publicado: (2013)

Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes
por: Colchester, Nancy T. H., et al.
Publicado: (2020)

Anti-HBc IgM and anti-delta screening by EIA method.
por: Kim, J. S., et al.
Publicado: (1986)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
por: Blase, Jennifer R., et al.
Publicado: (2022)

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
por: Stathopoulos, Panos, et al.
Publicado: (2022)

Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies
por: Magy, Laurent, et al.
Publicado: (2015)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

Competition between Serum IgG, IgM, and IgA Anti-Glycan Antibodies
por: Muthana, Saddam M., et al.
Publicado: (2015)

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia
por: Haerzschel, Andrea, et al.
Publicado: (2016)

Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells
Publicado: (1986)

Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8(+) and Natural Killer Cells
por: Anagnostouli, Maria C., et al.
Publicado: (2021)

Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum
por: Muthana, Saddam M., et al.
Publicado: (2016)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

To mag or not mag: that was the question?
por: Laybourne, S, et al.
Publicado: (2002)

Anti-glycan IgM repertoires in newborn human cord blood
por: Xia, Li, et al.
Publicado: (2019)

Specificity and biologic activities of novel anti-membrane IgM antibodies
por: Welt, Rachel S., et al.
Publicado: (2016)

Combined effect of medical therapy and rehabilitation in Chronic Ataxic Neuropathy with anti-Disialosyl IgM Antibodies (CANDA): a case report
por: Balestro, Giulio, et al.
Publicado: (2023)

Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
por: Wang, Beatrice T., et al.
Publicado: (2021)

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
por: Kohle, Felix, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2aiumusu9pilcdvcen3fp2i40